ADNeT researchers in the news

Due to the recent results from Phase 3 studies of amyloid-clearing drug lecanemab being announced, showing promising outcomes for slowing cognitive decline, media interest in the new drug treatment has been strong. As part of our leading dementia research network, ADNeT researchers from across our partner institutions appeared in several major news stories and interviews about the drug and what this means for the future of dementia research.

Professor Colin Masters, ADNeT Screening and Trials Lead and Professor in Dementia Research at the Florey Department of Neuroscience and Mental Health at the University of Melbourne, gave his insights on the results of lecanamab with ABC National Radio. You can listen to his interview here.